We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NextGen Sciences Appoints new CEO and Expands Service Offering
News

NextGen Sciences Appoints new CEO and Expands Service Offering

NextGen Sciences Appoints new CEO and Expands Service Offering
News

NextGen Sciences Appoints new CEO and Expands Service Offering

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NextGen Sciences Appoints new CEO and Expands Service Offering"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

NextGen Sciences has appointed Dr Mike Pisano as CEO, and has announced the expansion of its portfolio of services to include clinical protein biomarker monitoring.

As recently announced, Dr Pisano joins the Company from Proteomic Research Services (PRS), which was acquired by the NextGen Group in November 2006, where he was cofounder and CEO.

With over a decade of senior management experience in the pharmaceutical industry, Dr Pisano’s previous roles include Group Leader, Proteomics and Protein Production, Rhone-Poulenc Rorer Pharmaceuticals; Head, Protein Sciences, Aventis Pharmaceuticals; and Vice-President Proteomic R&D, Genomic Solutions, Inc. Dr. Pisano currently serves on the Scientific Advisory Board of several life sciences companies and instrumentation manufacturers.

The new protein biomarker services from NextGen Sciences include:

• Assay development and validation.

• Monitoring and verification of protein biomarkers from pre-clinical and clinical samples.

• Identification of putative protein biomarkers and proteins of interest.

The new biomarker services are underpinned by the Company’s core expertise in protein science, as well as investment in technologies such as the OrbiTrap and triple quad mass spectrometers from ThermoFisher. Integration of these technologies with the mass spectrometry-based technique of Multiple Reaction Monitoring (MRM) has enabled the Company to develop a high throughput platform for rapid and highly specific biomarker validation.

Commenting on the new services, Dr. Pisano said: “Our investment in leading technologies, in combination with the expertise of our scientists, enables us to offer customers the best possible services for clinical biomarker discovery and development programs.

We are already working with a number of major customers to develop robust, accurate and precise assays to meet the needs of their clinical biomarker projects. Through the acquisition of PRS and also in partnership with Kemp Biotechnologies, we can now offer our customers the most comprehensive range of products and services, which can be tailored to meet individual requirements for successful customer projects.”

Advertisement